CLINICAL_TRIALS
trial_result
· 2024-10-29
Clinical Trial Update: Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma [Phase 1]
Summary
Amgen's Phase 1 study of AMG 596 in EGFRvIII-positive glioblastoma has been terminated, and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Glioblastoma or Malignant Glioma | Phase 1 | Status: TERMINATED | Results posted: 2024-10-29